[1] 陈愉,宁莹,李可馨,等.子宫癌肉瘤60例临床病理及预后因素分析[J].现代妇产科进展,2024,33(2):87-91,103. [2] 谢玲玲,林仲秋.《2024 NCCN子宫肿瘤临床实践指南(第1版)》解读[J].中国实用妇科与产科杂志,2023,39(11):1122-1127. [3] 陈小兰,毛毳.藏族女性子宫癌肉瘤1例并文献复习[J].广州医药,2023,54(6):56-60. [4] 张茁,许文静,任晓楠,等.子宫癌肉瘤研究进展[J].现代妇产科进展,2022,31(12):952-955. [5] VOUTSADAKIS I A.Epithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Müllerian tumours:the role of ubiquitin proteasome system and therapeutic opportunities[J].Clin Transl Oncol,2012,14(4):243-253. [6] CHERNIACK A D,SHEN H,WALTER V,et al.Integrated molecular characterization of uterine carcinosarcoma[J].Cancer Cell,2017,31(3):411-423. [7] 吴林林,白杨,胡艳萍.子宫癌肉瘤临床病理特征及分子分型[J].中国妇产科临床杂志,2022,23(1):67-68. [8] 吴玲玲,夏燕,封扬,等.恶性中胚叶混合瘤6例临床病理学特征[J].安徽医药,2017,21(7):1234-1237. [9] 贾楠,张楚瑶,冯炜炜.子宫癌肉瘤41例临床病理分析[J].现代妇产科进展,2015,24(1):6-10. [10] DING X H,MA Z Y,WANG Y F,et al.Clinicopathological features of malignant mixed mesodermal tumor:Analysis of 50 cases.[J].Zhonghua bing li xue za zhi,2021,50(9):1008-1013. [11] WANG X,WANG S,YAO S,et al.The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor:A systematic review[J].J Ovarian Res,2022,15(1):104. [12] 王丹,徐柏,孙欣,等.卵巢恶性中胚叶混合瘤(癌肉瘤)2例临床分析并文献复习[J].中国生育健康杂志,2022,33(1):59-61. [13] 卢淮武,徐冬冬,赵喜博,等.《2024 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J].中国实用妇科与产科杂志,2024,40(2):187-197. [14] 毕莹莹,邢峰,程忠平.卵巢癌肉瘤的1例报告及其各组分分化起源探究[J].同济大学学报(医学版),2021,42(1):142-146. [15] FOX C,ALLEN N,SCHIMP V,et al.Ovarian teratoid carcinosarcoma is an aggressive tumor of probable Mullerian derivation with a carcinosarcomatous and mixed germ-cell morphology[J].Case Rep Oncol,2019,12(1):241-247. [16] DEL PAPA M,D'AMATA G,MANZI F,et al.Extragenital malignant mixed mesodermal tumor:A case report[J].Int J Surg Case Rep,2017(41):323-326. [17] 徐晓燕,翟瑞芳.子宫恶性中胚叶混合瘤一例并文献复习[J].中国药物与临床,2019,19(10):1643-1644. [18] 吴克姣,陈明光,刘继英.82例子宫内膜癌错配修复蛋白表达与临床病理特征的关系[J].广州医药,2023,54(12):44-48. [19] 郝金燕,邓晋芳,刘莉萍,等.12例卵巢子宫恶性中胚叶混合瘤临床病理分析[J].解放军医学院学报,2015,36(9):896-899. [20] 王雯雯,周怀君,凌静娴,等.女性生殖系统恶性中胚叶混合瘤22例临床特征分析[J].中国妇产科临床杂志,2019,20(4):317-320. [21] SAENZ D,FERNÁNDEZ J D,CÓBAR J P.Challenges in diagnosis and treatment:a case report on a mixed malignant Müllerian tumor[J].J Surg Case Rep,2023,2023(9):rjad523. [22] HEINZELMANN-SCHWARZ V,KIND A B,VETTER M,et al.Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?[J].J Cancer Res Clin Oncol,2020,146(3):695-704. [23] BELLONE S,HALMEN S,ENGLISH D P,et al.Solitomab,an EpCAM/CD3 bispecific antibody construct(BiTE),is highly active against primary uterine serous papillary carcinoma cell lines invitro[J].Am J Obstet Gynecol,2016,214(1):99.el-99.e8. [24] KALINCSÁK J,GŐCZE P,BÓDIS J,et al.Multimodal treatment of malignant mixed Müllerian tumor[J].Orv Hetil,2018,159(19):741-747. [25] KIM J.US findings of uterine and ovarian malignant mixed mesodermalTumors[J].Ultrasound Med Biol,2011,37(8)S118. [26] 邢笑宇,史惠惠,邓学利,等.13例卵巢癌肉瘤临床特征分析及相关文献回顾[J].现代妇产科进展,2024,33(2):137-141. |